Increased chemokine excretion in patients suffering from chronic kidney disease

Area of Science:

• Nephrology
• Immunology
• Biomarker Discovery

Background:

• Chronic kidney disease (CKD) involves leukocyte infiltration into the kidneys, driven by chemokines, exacerbating renal damage through inflammatory and fibrotic factors.
• Chemokines are implicated in the pathogenesis of chronic renal failure, highlighting their potential role in disease progression.

Purpose of the Study:

• To investigate serum and urine chemokine levels (CCL17, CCL20, CCL22, CXCL11) in CKD patients and healthy volunteers.
• To assess the suitability of these chemokines as biomarkers for monitoring CKD disease course and patient risk stratification.

Main Methods:

• Analysis of serum and urine chemokine levels in 114 CKD patients across various stages and 21 healthy controls.
• Measurement of fractional excretion of specific chemokines: CCL17, CCL20, CCL22, and CXCL11.
• Utilized receiver operating characteristic (ROC) curve analysis to evaluate predictive potential for CKD staging.

Main Results:

• Elevated fractional excretion of CCL22 was observed in CKD stages 2-5 compared to controls, and in stages 4-5 versus earlier stages.
• Fractional excretion of CCL20 and CXCL11 was significantly increased in advanced CKD stages (4-5) compared to controls and earlier stages.
• ROC analysis demonstrated the potential of chemokine excretion (CCL22, CCL20, CXCL11) to predict different CKD stages with significant area under the curve (AUC) values.

Conclusions:

• Fractional chemokine excretion, particularly CCL22, CCL20, and CXCL11, may serve as valuable biomarkers for monitoring CKD progression.
• These biomarkers could aid in risk assessment and facilitate personalized treatment planning for CKD patients.
• Further investigation into chemokine levels across different CKD etiologies is warranted.